Status:
COMPLETED
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions:
Bone Tumor
Eligibility:
MALE
18-65 years
Phase:
PHASE1
Brief Summary
A randomized, double-blind and parallel group study to compare the pharmacokinetic, safety and pharmacodynamic of MW032 and Xgeva® in healthy adults.
Detailed Description
This is a phase I, single center, randomized, double-blind and parallel group clinical trial. The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous injections o...
Eligibility Criteria
Inclusion
- Age: 18-65 years old (including 18 and 65 years old), healthy male subjects.
- Body mass index (BMI) within the range 19-28kg/m2.
- History, physical examination, laboratory tests and test related items of inspection were normal or mildly abnormal clinically insignificant.
- Volunteered to participate in this clinical trial, capable of giving written informed consentan.
- The subject (including the subject's partner) takes effective contraceptive measures.
Exclusion
- Nervous/mental, respiratory system, cardiovascular system, digestive system, blood and lymphatic system, endocrine system, skeletal and muscular system diseases, liver and kidney dysfunction, or any other diseases and physiological conditions that may affect the results of the study.
- Occurred or suffering from osteomyelitis or ONJ (mandibular necrosis) previously.
- Clinical laboratory abnormalities of clinical significance, or other clinical findings suggest clinically significant following diseases (including, but not limited to the gastrointestinal tract, kidney, liver, nerve, blood, endocrine, cancer, lung, immune, mental or cardiovascular disease).
- Subject has viral hepatitis (including hepatitis B and hepatitis C), AIDS antibodies, and Treponema pallidum antibodies.
- Those who have used the following drugs within 1 month or 5 half-lives (whichever is longer) before participating in this study, including but not limited to: estrogen-containing contraceptives, bisphosphonates, fluoride, hormone replacement Treatment (ie tibolone, estrogen, estrogen-like compounds, such as raloxifene), calcitonin, strontium, parathyroid hormone or its derivatives, vitamin D supplements (\>1000 IU/day), corticosteroids (inhaled or topical corticosteroids can be used 2 weeks before enrollment), anabolic hormone drugs, calcitriol, diuretics.
Key Trial Info
Start Date :
June 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 26 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04798326
Start Date
June 25 2019
End Date
February 26 2020
Last Update
March 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PKUCare Luzhong Hospital
Zibo, Shandong, China, 255400